Investors Judge Biotech Harshly: PDL BioPharma, MedImmune, Amgen Disappoint
Biotechnology investors could experience palpitations after this past quarter's dismal performance on the "The Pink Sheet" Index of NASDAQ stocks
You may also be interested in...
Two recently released studies could help Johnson & Johnson in its efforts to ward off competition for its anemia therapy Procrit (epoetin) from Amgen's second-generation erythropoietin product Aranesp (darbepoetin)
MedImmune's growing vaccine franchise and recently revised co-marketing arrangement for Synagis (palivizumab) may position the firm well for a takeover